Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?

Table 2 Distribution of follicle types between the groups

	Group 1 (Sham)	Group 2 (CP + Saline)	Group 3 (CP + Mtf)	Group 4 (Mtf)	Group 5 (Saline)	P
Primordial	10.4 ± 2.1^a	5.3 ± 1.4^a,b,c,d	9.6 ± 1.7^b	10.0 ± 2.6^c	10.3 ± 1.2^d	< 0.001
Primary	4.3 ± 2.2	3.3 ± 1.4^e	6.0 ± 1.9^e	4.6 ± 1.7	4.4 ± 2.1	< 0.001
Secondary	3.7 ± 1.1	4.0 ± 1.5	4.1 ± 1.9	4.4 ± 1.5	4.3 ± 1.4	> 0.05
Tertiary	1.1 ± 0.9	1.4 ± 0.5^f	1.8 ± 0.9^f	1.3 ± 0.8	1.0 ± 0.8	> 0.05
Graafian	0.4 ± 0.5^g	1.0 ± 0.6^g	0.7 ± 0.5	1.0 ± 0.6	0.7 ± 0.8	< 0.001

Note.^*p = Kruskal–Wallis test. (a) difference in primordial follicles between Group 1 and Group 2, p < 0.001; (b) difference in primordial follicles between Group 2 and Group 3, p < 0.001; (c) difference in primordial follicles between Group 2 and Group 4, p < 0.001; (d) difference in primordial follicles between Group 2 and Group 5, p < 0.001; (e) difference in primordial follicles between Group 2 and Group 3, p < 0.001; (f) difference in tertiary follicles between Group 2 and Group 3, p < 0.05; (g) difference in Graafian follicles between Group 1 and Group 2, p < 0.001

ISSN: 1757-2215